Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus KEFUROX IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus KEFUROX IN PLASTIC CONTAINER.
CEFUROXIME SODIUM vs KEFUROX IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 and PBP-1a/1b, leading to inhibition of transpeptidase activity and autolysin-mediated cell death.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
750 mg to 1.5 g IV every 8 hours; for severe infections, up to 3 g IV every 8 hours.
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
1.2-1.6 hours in adults with normal renal function. Extended to 15-22 hours in end-stage renal disease.
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: <1%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic